Stoke Therapeutics (STOK) has drawn fresh attention after recent trading left the stock at a last close of $31.62. Investors are weighing this price against its recent returns and current clinical development profile.

Over the past month, Stoke Therapeutics has seen a 7.26% 1 month share price return, while the year to date share price return of 2.33% sits alongside a very strong 1 year total shareholder return of 60.02%. This suggests recent momentum is still being digested after a very large 3 year total shareholder return of about 5.7x.

Scan Stoke Therapeutics alongside a hand picked 19 high quality undiscovered gems that pair strong recent returns with developing clinical or growth stories.

Stoke Therapeutics has a complex clinical story and a share price that has already moved a long way. The real test now is whether the current US$31.62 price fairly reflects that progress or stretches it.

Most Popular Narrative: 29.9% Undervalued

Against Stoke Therapeutics' last close of $31.62, the most widely followed narrative points to a fair value of $45.10, which implies a sizeable valuation gap based on long term assumptions about its genetic medicines pipeline.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

Want to see what sits behind that gap between price and fair value? The narrative leans heavily on rapid revenue expansion, a sharp margin swing, and a future earnings multiple that is usually reserved for market leaders. Curious how those moving parts fit together and what has to happen for the model to hold? The full story lays out the step by step assumptions behind that $45.10 figure.

Result: Fair Value of $45.10 (UNDERVALUED)

However, Stoke Therapeutics still faces key risks, including the possibility that pivotal Dravet data fall short of expectations and that long term safety findings weaken the current thesis.

Next Steps

With sentiment clearly mixed on Stoke Therapeutics, it makes sense to review the evidence yourself and move quickly while the data is still fresh. To see both the upside case and the areas investors are worried about in one place, start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Stoke Therapeutics?

Do not stop with Stoke Therapeutics when there are other opportunities worth your attention. Use the Simply Wall Street Screener to surface fresh, data driven ideas.

• Spot potential value early and review companies that screen as attractively priced with strong fundamentals using the 45 high quality undervalued stocks.
• Protect your downside first and focus on businesses that appear more resilient on key risk metrics through the 74 resilient stocks with low risk scores.
• Hunt for lesser known prospects that still show solid quality signals by scanning the 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.